近5日融资融券数据一览见下表： 证券之星消息，截至2025年12月10日收盘，振德医疗(603301)报收于72.37元，下跌2.28%，换手率 2.64%，成交量7.02万手，成交额5.04亿元。 12月10日的资金流向数据方面，主力资金净流出3120.74万元，占总成交额6.19%，游资资金净流入 1403.95万元，占总成交额2.79%，散户资金净流入1716.79万元，占总成交额3.41%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-10 | 72.37 | -2.28% | -3120.74万 | -6.19% | 1403.95万 | 2.79% | 1716.79万 | 3.41% | | 2025-12-09 | 74.06 | 0.07% | 1.06亿 | 12.01% | -5365.29万 | -6.05% | -5281.40万 | -5.96% ...

Core Viewpoint - The stock of Zhendemedical (603301) has experienced a decline, with a closing price of 88.04 yuan on November 13, 2025, down by 2.93% from the previous day, indicating a negative trend in investor sentiment and market performance [1][2]. Financial Performance - For the first three quarters of 2025, Zhendemedical reported a main business revenue of 3.184 billion yuan, a year-on-year increase of 1.88%. However, the net profit attributable to shareholders was 203 million yuan, a decrease of 33.91% year-on-year [5]. - In Q3 2025, the company achieved a single-quarter main business revenue of 1.084 billion yuan, a slight increase of 0.1% year-on-year, but the net profit attributable to shareholders fell by 48.47% to 75.42 million yuan [5]. Market Activity - On November 13, 2025, the net outflow of main funds was 26.33 million yuan, accounting for 3.58% of the total transaction amount, while retail investors saw a net inflow of 48.40 million yuan, representing 6.59% of the total transaction amount [1][2]. - The financing balance on November 13, 2025, was 1.749 billion yuan, with a net repayment of 12.19 million yuan in financing [3]. Industry Comparison - Zhendemedical's total market capitalization is 23.458 billion yuan, significantly higher than the industry average of 11.676 billion yuan, ranking 9th out of 124 in the medical device industry [5]. - The company's net profit margin stands at 6.61%, below the industry average of 9.57%, indicating potential challenges in profitability compared to peers [5]. Stock Metrics - The price-to-earnings (P/E) ratio for Zhendemedical is 86.59, which is considerably higher than the industry average of 60.24, suggesting that the stock may be overvalued relative to its earnings [5]. - The gross margin for Zhendemedical is 33.93%, which is lower than the industry average of 51.22%, indicating less efficiency in cost management compared to competitors [5].

Core Viewpoint - Zhendemedical (603301) experienced a significant increase in stock price, closing at 99.94 yuan on November 5, 2025, with a rise of 5.54% and a trading volume of 20.49 million shares, indicating strong market interest [1][2]. Financial Performance - For the first three quarters of 2025, Zhendemedical reported a main business revenue of 3.184 billion yuan, a year-on-year increase of 1.88%, while the net profit attributable to shareholders was 203 million yuan, a decline of 33.91% [5]. - In Q3 2025, the company achieved a single-quarter main business revenue of 1.084 billion yuan, a slight increase of 0.1% year-on-year, but the net profit attributable to shareholders fell by 48.47% to 75.42 million yuan [5]. Market Activity - On November 5, 2025, the net inflow of main funds was 169 million yuan, accounting for 8.45% of the total trading volume, while retail investors saw a net outflow of 153 million yuan, representing 7.62% of the total [1][2]. - The financing data indicated a net repayment of 14.08 million yuan on the same day, with a financing balance of 1.218 billion yuan [3]. Industry Comparison - Zhendemedical's total market capitalization is 26.629 billion yuan, significantly higher than the industry average of 11.527 billion yuan, ranking 8th out of 124 in the medical device sector [5]. - The company's net profit margin stands at 6.61%, below the industry average of 9.57%, and its gross margin is 33.93%, compared to the industry average of 51.22% [5]. Institutional Ratings - In the past 90 days, two institutions have given a buy rating for Zhendemedical, with an average target price of 58.0 yuan [6].

Core Viewpoint - Zhendemedical (603301) experienced a significant price increase of 9.99% on October 10, 2025, closing at 56.46 yuan, with a trading volume of 214,500 hands and a total transaction value of 1.195 billion yuan [1] Financial Performance - The company reported a main revenue of 2.1 billion yuan for the first half of 2025, a year-on-year increase of 2.83%, while the net profit attributable to shareholders was 128 million yuan, a decrease of 20.7% year-on-year [5] - The second quarter of 2025 saw a single-quarter main revenue of 1.109 billion yuan, up 2.79% year-on-year, and a net profit of 76.52 million yuan, down 12.76% year-on-year [5] Market Activity - On October 10, 2025, the net inflow of main funds was 41.59 million yuan, accounting for 3.48% of the total transaction value, while retail investors saw a net inflow of 22.58 million yuan, representing 1.89% of the total transaction value [1] - Over the past five days, the stock has seen fluctuations in fund flows, with notable net inflows and outflows from different investor categories [2] Financing and Margin Trading - On October 10, 2025, the company had a financing balance of 806 million yuan, with a net purchase of 147 million yuan in financing, ranking 12th in the market [3] - The margin trading data indicates a total margin balance of 806 million yuan, with a margin selling of 1,200 shares and a remaining margin of 14,700 shares [3] Industry Comparison - Zhendemedical's total market capitalization is 15.044 billion yuan, which is higher than the industry average of 12.06 billion yuan, ranking 19th among 123 companies in the medical device sector [5] - The company's gross profit margin stands at 34.19%, significantly lower than the industry average of 51.85%, ranking 100th in the industry [5]

Core Viewpoint - Zhendermedical's stock closed at 24.6 yuan, up 1.74%, with a rolling PE ratio of 18.06, marking a 215-day low, and a total market value of 6.555 billion yuan [1] Group 1: Company Performance - For Q1 2025, the company reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] - As of March 31, 2025, the number of shareholders increased to 24,690, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 59.32, with a median of 39.97, placing Zhendermedical at 38th in the industry ranking [1][2] - Other companies in the industry have varying PE ratios, with the highest being 20.96 for Antu Biology and the lowest at 11.61 for Jiuan Medical [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhendermedical, which closed at 23.68 yuan with a PE ratio of 17.38, marking a new low in 165 days, and a total market capitalization of 6.31 billion yuan [1][2] - The average PE ratio for the medical device industry is 56.58, with a median of 39.97, positioning Zhendermedical at 37th place within the industry [1][2] - As of March 31, 2025, Zhendermedical has 24,690 shareholders, an increase of 1,808 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Zhendermedical specializes in the research, production, and sales of medical and health products, with key offerings in basic care, surgical infection control, pressure treatment, stoma care, and modern wound care [1] - The latest quarterly report for Q1 2025 shows Zhendermedical achieved a revenue of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.24 million yuan, reflecting a year-on-year decrease of 30.19%, with a gross margin of 34.28% [1]

Core Viewpoint - Zhendermedical's stock closed at 23.22 yuan, down 1.32%, with a rolling PE ratio of 17.04 times and a total market value of 6.187 billion yuan [1] Company Summary - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including provincial-level key enterprise research institutes and high-tech enterprise certifications [1] - For Q1 2025, Zhendermedical reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Zhendermedical at the 36th position in the industry [1] - The industry includes various companies with differing PE ratios, such as Ji'an Medical at 11.18 times and Yuyue Medical at 20.19 times, indicating a wide range of valuations within the sector [2]

最新一期业绩显示，2025年一季报，公司实现营业收入9.92亿元，同比2.87%；净利润5124.19万元，同 比-30.19%，销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗17.3716.371.1063.04亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0516.231.34237.81亿3山东药玻16.1716.221.86152.96亿4新华医疗16.9415.701.38108.60亿6奥美医疗 17.5417.191.8063.39亿7九强生物17.9216.672.2088.77亿8康德莱18.7518.761.5540.40亿9维力医疗 18.7920.082.3644.05亿10奥泰生物19.3120.361.5661.58亿11鱼跃医疗20.2319.842.73358.29亿12安图生物 21.1920.232.72241.60亿 8月12日，振德医疗今日收盘23.66元，上涨3.59%，滚动市盈率PE（当前股价与前四 ...

Core Viewpoint - Zhendermedical's stock closed at 22.84 yuan, up 2.79%, with a rolling PE ratio of 16.76, marking a new low in 158 days, and a total market value of 6.086 billion yuan [1] Company Summary - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including provincial-level key enterprise research institutes and high-tech enterprise certifications, and has passed the national high-tech enterprise review [1] - For Q1 2025, Zhendermedical reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Zhendermedical at 35th in the industry ranking [1] - As of Q1 2025, three institutions held shares in Zhendermedical, with a total of 1.4513 million shares valued at 3.1 million yuan [1] - The industry average market value is 11.897 billion yuan, with Zhendermedical's market value significantly lower at 6.086 billion yuan [2]

Core Viewpoint - The stock of Zhendemedical (603301) has shown a decline in price and mixed capital flow, indicating potential volatility in the market [1][2]. Financial Performance - As of August 6, 2025, Zhendemedical's stock closed at 22.08 yuan, down 1.3% with a trading volume of 27,700 hands and a transaction amount of 61.39 million yuan [1]. - The company reported a main revenue of 992 million yuan for Q1 2025, a year-on-year increase of 2.87%, while the net profit attributable to shareholders was 51.24 million yuan, a decrease of 30.19% year-on-year [4]. - The company's gross profit margin stands at 34.28%, which is significantly lower than the industry average of 51.31% [4]. Capital Flow Analysis - On August 6, 2025, the net outflow of main funds was 5.89 million yuan, accounting for 9.6% of the total transaction amount, while retail investors saw a net inflow of 7.72 million yuan, representing 12.57% of the total [1]. - Over the past five days, the financing balance has increased, with a net financing purchase of 2.25 million yuan on August 6, 2025, contributing to a cumulative net purchase of 14.04 million yuan over three days [2]. Industry Comparison - Zhendemedical's total market value is 5.883 billion yuan, which is below the industry average of 11.525 billion yuan, ranking 59th out of 123 companies in the medical device sector [4]. - The company's price-to-earnings ratio (P/E) is 28.7, significantly lower than the industry average of 61.65, indicating a potentially undervalued stock [4]. Institutional Ratings - In the last 90 days, two institutions have rated Zhendemedical with a "buy" recommendation, and the average target price set by institutions is 27.13 yuan [5].